AFT Pharmaceuticals (NZE:AFT, ASX:AFP) expects to achieve record sales of more than AU$200 million in fiscal 2025, up from AU$56 million in fiscal 2015 and AU$106 million in fiscal 2020, according to a Monday filing with the Australian and New Zealand bourses.
The upbeat outlook comes despite sales disruptions seen in the first half. The pharmaceutical company said it targets to achieve AU$300 million turnover on a rolling annual basis by the end of 2027.
AFT Pharmaceuticals' Kiwi shares were up past 1% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。